Pertuzumab, a humanized monoclonal antibody and the first in the class of agents called the HER2 dimerization inhibitors, impairs the ability of HER2 to bind to other members of the HER family.

Quality in oncology healthcare is a moving target for stakeholders (patients, healthcare providers, and payers) in systematically identifying, planning, and executing approaches to improving quality.

Quality in oncology healthcare is a moving target for stakeholders (patients, healthcare providers, and payers) in systematically identifying, planning, and executing approaches to improving quality.

Quality in oncology healthcare is a moving target for stakeholders (patients, healthcare providers, and payers) in systematically identifying, planning, and executing approaches to improving quality.

This educational program addresses health care professionals' need to be educated on current and emerging evidence-based scientific data for accurate and timely clinical evaluation of patients with breast cancer.

This educational program addresses health care professionals' need to be educated on current and emerging evidence-based scientific data for accurate and timely clinical evaluation of patients with breast cancer.

This educational program addresses health care professionals' need to be educated on current and emerging evidence-based scientific data for accurate and timely clinical evaluation of patients with breast cancer.

Managing breast cancer across the continuum of care, including early breast cancer, metastatic disease, and survivorship is a complex and rapidly evolving task.

Managing breast cancer across the continuum of care, including early breast cancer, metastatic disease, and survivorship is a complex and rapidly evolving task.

Clear evidence is available regarding the wide variation in the quality of cancer care delivered in the United States. These findings led the Institute of Medicine (IOM) in 1999 to call for major changes in cancer care delivery to improve quality and enhance the patient experience.